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Abstract 
 
Background: High rates of anxiety disorders, particularly Obsessive 
Compulsive Disorder (OCD) are reported in people with Autism Spectrum 
Disorders (ASD). Group cognitive behavioural (CBT) treatment has been 
found effective for anxiety in young people with ASD but  not been OCD 
specific. One uncontrolled pilot study of individual CBT for OCD for adults 
with ASD showed good treatment efficacy.  
 
Methods: Forty-six adolescents and adults (mean age 26.9 years, 35 Males) 
with ASD and comorbid OCD were randomized to  CBT for OCD or Anxiety 
Management (AM), a plausible control treatment. Treatments were matched 
in duration (mean of 17.4 sessions CBT; 14.4 sessions AM), the Yale Brown 
Obsessive Compulsive Severity Scale (YBOCS) as primary outcome 
measure and evaluations blind to treatment group. Treatment response was 
defined as >25% reduction in YBOCS total severity scores.  
 
Results: Both treatments produced a significant reduction in OCD symptoms,  
within-group effect sizes of 1.01  CBT group and 0.6 for the AM group. There 
were no statistically significant differences between the two groups at  end of 
treatment, althoughmore responders in the CBT group (45% vs 20%). Effect 
sizes for self-rated improvement were small (0.33 CBT group; -0.05 AM 
group).  Mild symptom severity was associated with improvement in the AM 
but not the CBT group. Family/carer factors were important for both groups, 
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in that increased family accommodation was associated with poorer 
outcome. 
 
Conclusions: Evidence-based psychological interventions, both anxiety 
management and CBT were effective in treating comorbid OCD in young 
people and adults with ASD 
The study was registered as a controlled trial (ISRCTN87114880). 
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Introduction 
 
Autism Spectrum Disorder (ASD) is characterized by qualitative impairments 
in social communication and a restricted, repetitive pattern of interests and 
behaviors, emerging in early childhood and enduring across the lifespan. 
High rates of anxiety disorders have been reported in both young people1 
and adults2,3 with Autism Spectrum Disorders (ASD). Rates of disorders in 
childhood range from 11-84% and a selective pattern of anxiety disorders, 
namely Social Anxiety, Obsessive Compulsive Disorder (OCD) and specific 
Phobias has been reported4,5.  
 
Childhood anxiety reduces social interactions, self-esteem and impoverishes 
social skills  in typically developing children6 thereby exacerbating problems  
characteristic of ASD. Furthermore, behavioural problems have been noted 
to be more likely related to fears in children with ASD than other groups7.   
 
Co-morbid OCD has been reported to occur in 30% of young people with 
ASD3,8 and high rates of OCD have also been reported in adults with ASD 
both with and without intellectual disability9,10. OCD has considerable impact 
on quality of life for both sufferers and carers and is listed in the World 
Health Organisation’s top 20 leading causes of years lived with disability 
among individuals aged 15-4411.  OCD is a treatable anxiety disorder with 
good evidence for the effectiveness of empirically based psychological 
treatments such as Cognitive Behaviour Therapy (CBT)12.  
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There is emerging evidence that CBT may be effective in ameliorating 
distressing and debilitating anxiety in people with ASD.  Trials of Group CBT 
interventions for anxiety symptoms5 and anxiety disorders13,14,15 adapted for 
children with ASD have reported promising results.   
 
To date, most adult treatment studies of CBT in ASD have been confined to 
single case reports – for example its effectiveness for depression16 and 
social anxiety disorder17.  More recently, we reported18 preliminary evidence 
from an uncontrolled pilot study of CBT for OCD in 24 adults with ASD and 
co-morbid OCD: we found that of the 12 adults who received CBT for OCD, 
7 (58%) showed a good treatment response in comparison to 2 (16%) in the 
Treatment as Usual (TAU) group with a standardized effect size (Cohen’s d) 
for CBT of 1.01. This is reasonably consistent with published treatment 
response rates for behavior therapy (59%) and CBT (67%) in adults with 
OCD without ASD19.  
In summary, there is evidence of high rates of anxiety disorders, particularly 
co-morbid OCD, in both young people and adults with ASD. Results of both 
individual and group systematic psychological treatment evaluations for 
anxiety disorders in children and adolescents with ASD have been 
promising, but to date none have been OCD-specific. There is preliminary 
evidence that CBT may be effective for OCD in ASD as compared to TAU 
but this requires replication and comparison with other potentially effective 
approaches for this group.   
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The aims of the present study were to systematically evaluate CBT for OCD 
adapted for people with ASD via a RCT comparing the new intervention with 
a plausible control treatment.  
 
 
METHODS 
Participants 
Participants were recruited from specialist ASD clinics, specialist adult and 
pediatric OCD clinics and generic child and adult mental health services.  
Participants were individuals with a confirmed diagnosis of an ASD, Verbal 
IQ > 70 and co-morbid Obsessive Compulsive Disorder (OCD) aged 
between 14 and 65 years. Participants were excluded if they had current 
psychotic symptoms, a current episode of major depression, uncontrolled 
epilepsy or current substance misuse. Participants were included only if 
psychiatric medication was stable in the 6 weeks prior to study entry and if 
they had a baseline Yale Brown Obsessive Compulsive Scale (YBOCS) 
severity rating of >16, typically used for inclusion in clinical trials20. Diagnosis 
of ASD was confirmed using the Autism Diagnostic Interview (ADI). 
Diagnostic information was supplemented by the Autism Diagnostic 
Observation Schedule (ADOS)21 for all participants. Assessment of other co-
morbid psychiatric diagnoses and to confirm the presence of OCD was 
carried out using the MINI 5.0 neuropsychiatric interview22.  
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Delineating anxiety based obsessions and compulsions from the repetitive 
routines and behaviors and circumscribed interests characteristic of ASD 
was completed using the YBOCS-Symptom Checklist (YBOCS-SCL) and 
according to the procedures developed in an earlier phenomenological 
study10 which were detailed in the study manual. In brief, at the start of each 
clinical interview care was taken to ensure that the participant was 
cogniscent of the phenomena to be rated, that the discomfort and anxiety 
basis for each potential OC symptom was clearly established using visual 
tools if necessary. Eliciting of symptoms was achieved if needed by 
enquiring about daily routines in total before gathering further 
phenomenological information. Communication style and preferences of 
each individual were also taken into account when administering the Y-
BOCS. The presence of obsessions/compulsions was not recorded unless 
the ego-dystonic basis for unwanted internal phenomena and a resistance 
to/recognition of the excessive nature of compulsions could be established.  
 
All participants read an information sheet and signed consent forms to take 
part in the study with developmentally appropriate information and assent 
forms for participants aged 14-16 years.  
 
The study was registered as a controlled trial (ISRCTN87114880) with 
ethical approval granted by the local ethics committee.  
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Study design 
 
A manual outlining ASD specific adaptations to standard CBT for OCD was 
developed on the basis of a case note review of the pilot study18, expert 
recommendations23,24 and the literature on cognitive and neuropsychological 
function in ASD where deficits in emotion recognition and executive function 
are reported. Standard cognitive behavior therapy (CBT) for OCD was 
adapted by (i) ensuring the building blocks for treatment (i.e. understanding 
and differentiating emotions, particularly anxiety, and making links between 
thoughts, feelings and behaviors) were in place, (ii) If required, educational 
sessions about understanding and rating anxiety were provided before 
moving on to present the rationale for treatment, (iii) visual tools and 
concrete/special interest related analogies were used to convey 
psychological concepts and (iv) a structured and therapist-directed approach 
to sessional and homework content was taken.    
 
The CBT treatment was predominantly Exposure and Response Prevention 
(ERP) based and this was conducted in the usual hierarchal fashion both in 
sessions and as homework. Post-hoc review of the treatment records 
identified that an average of 10 (s.d. = 5.4) ERP homework tasks were set 
and the compliance rate for ERP homework tasks was 79%. Cognitive 
methods were also used to help individuals test out OCD and anxiety related 
beliefs if appropriate. Post-hoc review identified that a mean of 2.7 (s.d = 
3.2) sessions contained some cognitive techniques in the CBT group. 
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The control or comparison treatment was specified as Anxiety Management 
(AM) to ensure that any treatment effects were solely due to the adapted 
CBT for OCD rather than therapist contact, psycho-education about anxiety 
and general anxiety reduction techniques. Furthermore, the general lack of 
access to psychological treatment services for adults with ASD suggested 
that TAU or a no-treatment condition would unfairly advantage the 
experimental treatment and would not represent an adequate test of 
effectiveness.  
 
The AM manual was developed for the present study by one of the authors 
(MF) and was based on previous work25, 26. It comprised 8 modules which 
were adapted for ASD by including visual aides or concrete examples. The 
modules included education about anxiety, diaphragmatic breathing and 
practice, progressive muscle relaxation education and practice, education 
about mood, healthy habits and problem-solving. The AM manual did not 
contain any of the ‘active’ ingredients considered important in effective 
treatment of OCD i.e. ERP or any cognitive strategies addressing OCD-
related beliefs.  
 
The treatments were matched for duration (up to 20 sessions) and amount of 
therapist contact (approximately 1 hour per session). Treatment completers 
were defined as attending at least 7 sessions. Treatment duration was 
specified as up to 20 sessions as prior experience had suggested that a 
longer assessment and orientation to therapy phase was necessary for 
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some individuals with ASD. For further details regarding the treatments, see 
Supplemental Material. 
The treating therapists were all clinical psychologists (n=4) trained within a 
cognitive behavioral framework who had extensive experience in treating 
OCD in both young people and adults. All had received post-qualification 
training in CBT for OCD having attended workshops delivered by OCD 
specialists. All therapists delivered both treatments on a randomly allocated 
basis. Three pilot cases (2 young people and 1 adult with ASD) were treated 
with the CBT manual prior to commencing the RCT for feasibility and user 
perspective purposes. This also allowed the trial therapists to be trained in 
working more specifically with people with ASD and OCD. As therapists who 
had worked in specialist OCD clinics, they had previous experience of 
working with people with ASD. A consultant clinical psychologist with 
expertise in both adult and pediatric cases (DMC) provided supervision for 
the CBT cases.  
 
Randomization procedure 
Participants were randomized to the CBT or AM groups using a table of 
random numbers (1:1 ratio) managed by an investigator who was part of the 
Trial Management Committee but not a treating therapist.   
 
Review of the study protocol by the ethics committee recommended that the 
‘other’ treatment should be offered to participants on completion of the first 
treatment. Thus, participants were informed via the study information sheet 
 12
that they could try the other treatment at or after 1 month follow-up following 
completion of the first treatment if they wished. 
 
Treatment Fidelity and Therapist Allegiance 
A random proportion of cases (20%) were audio recorded to ensure 
treatment fidelity. All treatment sessions were recorded and 20 percent of 
these recordings were then randomly selected and rated by an independent 
therapist, blind to treatment condition and outside of the clinical trial, as to 
whether the session contained OCD targeted interventions such as ERP or 
exploration of OCD-related beliefs. There was no evidence of cross-
contamination on the recordings i.e. none of the AM sessions were recorded 
as containing any elements of CBT for OCD.  
Outcome Measurement   
Symptom Ratings were made by assessors blind to treatment group prior to 
commencing treatment (i.e. no more than 4 weeks before the 1st treatment 
session), end of treatment (1 week after the final treatment session), and at 
1, 3, 6 and 12 month follow-up. Assessors were all trained clinicians 
experienced in administering the YBOCS and interviewing people with ASD. 
In order to address the validity of the blinding procedure, blind assessors 
were asked to complete a questionnaire at each assessment point noting 
which they thought was the randomization group and if this was (a) a 
random decision, (b) revealed by the participant or (c) due to clinical 
improvement27. Of the treatment completers, this section was not completed 
in 8 (20%) of cases. None of the assessors were ‘unblinded’ to treatment 
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group (i.e. cited (b) as the reason for their choice of treatment group). Blind 
assessors were accurate in their assignment of treatment group in 24 (60%) 
of cases. They described their choice as ‘random’ in 30 (75%) of cases. In 
18 (45%) of cases clinical improvement was also cited as a reason for group 
assignment.  
 
Primary Outcome 
The Yale Brown Obsessive Compulsive Scale (YBOCS)27 total severity 
rating was the primary outcome measure. In addition to the 10 item severity 
scale, the insight item from the Y-BOCS (Y-BOCS item 11) was also 
included with the interviewer being asked to document ‘what is the worst 
thing that the patient worries will happen if she/he did not respond to 
obsessive thoughts or urges to perform compulsions?’ and then rating the 
extent to which the patient is certain that the feared consequence is 
reasonable and will actually occur ranging from (0) ‘certain that the feared 
consequence will happen’ to (5) ‘certain that the feared consequence will not 
happen’. 
 A reduction of at least 25% on the YBOCS severity rating scale is 
considered to be a sensitive but not specific measure of treatment 
response28. A YBOCS total score of ≤ 12 for 1 week or more was used to 
define remission28 with remission lasting for longer than 1 month being 
defined as recovery.  
 
Secondary Outcome 
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A broad range of outcome measures, including assessment of other anxiety 
disorders was employed.  
 
Clinical Global Impression (CGI) and CGI Improvement (CGIi) Rating 
Scales29  
 
Dimensional Yale Brown Obsessive Compulsive Scale (D-YBOCS)30  
The D-YBOCS is a semi-structured interview to ascertain the presence and 
severity of 6 symptom dimensions of OCD. Each symptom dimension is 
rated for severity (0-15) with a global rating considering severity overall and 
global impairment (0-30).  
 
Self-Report (Adult) – Measures comprised the Obsessive Compulsive 
Inventory-Revised (OCI-R)31; Beck Depression Inventory (BDI)32, Beck 
Anxiety Inventory (BAI)33; Liebowitz Social Anxiety Scale (LSAS)34, and the 
Work and Social Adjustment Scale (WSAS)35 . 
 
Self-Report (Youth ages 14-18) – OCI-R, BDI-Youth36; WSAS, and the 
Spence Children’s Anxiety Scale (SCAS)37.  
 
Treatment Satisfaction - All participants were asked to rate their satisfaction 
with the treatment they had received on an 8-point visual analogue scale 
ranging from (0) ‘not at all satisfied’ to (8) ‘very much satisfied’. 
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Informant report (all participants) – A person who knew the participant well 
such as parent, carer or spouse was asked to complete the Children’s 
Obsessive Compulsive Inventory-Parent Version (PR-CHOCI-R)38 at each 
measurement point. Severity scores can be obtained by summing up the 
item responses to give ‘compulsions impairment (0-24), obsessions 
impairment (0-24) and total impairment (0-48). Informants were also asked 
to complete the Family Accommodation Scale-Parent Report (FAS-PR)39  
where 13 items relating to the provision of reassurance, modification of 
home routines etc are rated on a 5 point scale with a possible maximum 
score of 52. A total score of 13 is generally used as a cut-off to indicate 
clinically meaningful accommodation of OCD symptoms and this has been 
associated with treatment outcome in pediatric OCD40 . 
 
Correspondence between self-administered, clinician-administered and 
informant-administered measures of symptom content and severity  
There were modest but significant correlations between self and informant 
reports of symptom severity and clinician-administered pre-treatment 
measures. Furthermore, the sub-scales of the OCI-R were associated with 
the relevant symptom dimensions on the D-YBOCS (see Table 1).  
 
-Table 1 about here- 
 
 
 
 16
Power analysis 
Based on the data from the pilot study18 a sample size calculation showed 
that in order to detect statistically significant differences between the groups 
on the primary outcome measure (YBOCS total severity rating) at alpha 5% 
and 80% power, 19 participants would be required for each randomization 
group. We recruited 23 participants in each group, allowing for 4 dropouts in 
each treatment arm. 
 
Data Analysis 
 
Independent t-tests and χ2 tests were used to consider any pre-treatment 
differences between the groups on symptom measures and demographics.  
 
Analysis of covariance (ANCOVA) were carried out on the primary outcome 
measure controlling for baseline symptom severity to investigate any 
difference between the two groups at the end of treatment. Repeated 
measures analyses of variance were used to detect pre-post treatment 
changes in the AM and CBT groups. Effect sizes were calculated using 
Cohen’s d. All of the analyses were intention to treat and where outcome 
data was not available, pre-treatment scores were not carried forward 41. 
 
Results 
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Participant flow  
Seventy-five people were referred to the study, 8 (10.7%) were self-referrals, 
24 (32%) were referred from community mental health services, 21 (28%) 
were referred by specialist ASD services, 11 (14.7%) were referred by 
specialist anxiety disorder clinics, 4 (5.3%) were referred by voluntary sector 
services and referral information was missing for 7 (9.4%). Seventeen 
(22.6%) of these 75 individuals did not meet eligibility criteria for the study 
(see Figure 1), 2 people were eligible but geography prevented participation 
and 10 people did not consent to take part.  
 
Twenty three people were randomized to each of the 2 treatment groups 
(AM and CBT) with 20 treatment completers in each group.    
 
Figure 1 about here 
 
Participants in the treatment groups were involved in the treatment arm of 
the study for equivalent periods of time. The mean number of weeks 
between pre-treatment and end-of-treatment ratings were: AM group = 23.74 
(sd=10.37); CBT group =27.06 (sd=10.27). The mode or most usual length 
of treatment in weeks was 25.  
 
 
Demographics and Clinical features 
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Independent samples t-tests revealed no differences between the groups for 
the mean domain and total scores on the ADOS, Verbal IQ, age, or pre-
treatment symptom scores (see Table 2).  
 
The treatment groups did not differ with respect to gender distribution (AM 
group 69.6%, CBT group 82.6% male), or the proportion of those under the 
age of 18 (AM group n=6 (26.1%), CBT group n=3 (13%) youth protocol).   
 
Table 2 about here 
 
The groups did not differ significantly in respect of OCD symptom 
dimensions with Contamination Obsessions and related compulsions 
reported by 18 (78.2%) of the AM group and 20 (86.9%) of the CBT group, 
Aggressive/Harm obsessions by 17 (73.9%) of the AM group and 14 (60.8%) 
of the CBT group, Sexual/Religious obsessions by 5 (21.7%) of the AM 
group and 9 (39.1%) of the CBT group; Symmetry obsessions by 16 (69.5%) 
of the AM and 15 (65.2%) of the CBT group; Hoarding obsessions by 9 
(39.1%) of the AM and 14 (60.8%) of the CBT group and miscellaneous 
obsessions/compulsions endorsed by 10 (43.3%) of the AM group and 9 
(39.1%) of the CBT group. The AM and CBT groups endorsed a mean of 3.1 
(sd=1.2) and 3.3 (sd=1.4) OCD symptom dimensions respectively.   
  
Number of Sessions 
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The mean number of treatment sessions was marginally greater in the CBT 
(17.43; sd=4.3) than in the AM condition (14.43; sd=5.3) (t=-2.022, df=42, 
p=.05, 95% C.I. -5.98 to -.006).   
  
 
Treatment Response (acute phase) 
Table 3 shows, for blind clinical assessor, self and informant ratings, the 
means and standard deviations for each measure at pre, post and 1 month 
follow-up treatment, percent improvement change between pre- and post-
treatment and pre-treatment and 1 month follow-up, the mean difference, 
95% confidence intervals and within-group effect sizes.  In terms of missing 
data, Y-BOCS and D-YBOCS ratings were available for all participants in 
both groups at the start of treatment, 20 in the CBT group and 20 in the AM 
group at the end of treatment, and 18 in the CBT and 17 in the AM group at 
1 month follow-up.  For the self-report measures, the OCI-R was completed 
by 20, 17 and 17 in the CBT group and 19, 17 and 17 in the AM group at the 
start, end and 1 month post treatment respectively. There was a similar rate 
of completion with the other self-report measures. The Informant measures 
were completed by 15, 14 and 11 in the CBT group and 14, 11 and 9 in the 
AM group at the start, end and 1 month post treatment respectively. 
 
Table 3 about here 
 
ANCOVA, controlling for pre-treatment YBOCS severity ratings, detected no 
significant differences between the treatment groups on the primary outcome 
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measure (YBOCS total severity scores) at end of treatment (F1,37,=1.127, 
p=0.295).   
 
In the CBT group, univariate repeated measures ANOVAS established 
significant changes in YBOCS total severity scores from pre-treatment to 
end of treatment (F1,19,=15.089, p=.001). In the AM group, there were also 
significant changes in YBOCS total severity ratings from pre-treatment to 
end of treatment (F1,19,=20.169, p<.0001). 
 
Within-group treatment effect sizes on the YBOCS were large and could be 
considered clinically meaningful in the CBT group (1.15) and medium in the 
AM group (0.6).   
 
There were more treatment responders (i.e. had a >25% reduction in 
YBOCS total severity ratings) in the CBT group as compared to the AM 
group (9/20 (45%) vs 5/20 (20%) respectively). However this difference in 
response rate was not statistically significant (X2=1.72, df=1, p=.160).  When 
a more stringent rating of treatment response i.e. a CGI ‘much or very much 
improved’ combined with a >35% reduction in YBOCS total severity ratings 
was considered, 6/20 (30%) of the CBT group achieved treatment response 
compared with 2/20 (10%) of the AM group. Again the groups did not differ 
significantly in the proportion of treatment responders. Slightly more 
participants in the CBT group were classified as remitted cases (i.e. with a 
YBOCS total severity rating of ≤ 12 1 week after treatment ended) as 
compared with the AM group (5/20 (20%) vs 3/20 (15%)) but this difference 
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was not statistically significant. 
 
Standardized effect sizes to further compare the 2 treatments were 
calculated for end of treatment primary outcome ratings using Cohen’s d 
(mean CBT – mean AM/pooled).  Effect sizes were 0.4 for the YBOCS total 
severity rating, 0.4 for YBOCS obsessions severity, 0.2 for YBOCS 
compulsions and 0.3 for Clinical Global Impression, all indicating a small 
advantage for CBT over AM after treatment.   
 
Treatment Satisfaction 
There were no differences between the 2 treatment groups as to their 
reports of satisfaction with the treatments they had received: AM Group 
mean satisfaction score=5.60 (sd=2.131); CBT Group mean satisfaction 
score=4.9 (sd=2.3), t=.809(df=27) p=.425. 
 
Maintanance of gains at long term follow-up 
In the CBT group, there were significant changes in YBOCS total severity 
scores from pre-treatment to 1-month follow-up (F1,17,=10.530, p=.005), 3-
month follow-up (n=10; F1,9,=11.602, p=.008), 6-month follow-up (n=12, 
F1,11,=10.823, p=.007) and 12-month follow-up (n=11; F1,10,=9.831, p=.011). 
The stability of the change over time can be seen in Figure 2.   
 
 
Figure 2 about here 
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Cross-Over Cases 
Nine (39%) participants in the AM group, compared with 3 (13%) participants 
in the CBT group asked to ‘cross-over’ or try the other treatment either at or 
after the 1 month follow-up point (X2 = 4.05, df=1, p=.044).  
 
Eight of the 9 participants originally randomized to AM who ‘crossed-over’ to 
CBT completed the second treatment and attended for symptom ratings 
(AM+CBT). One participant was not available for end of treatment ratings 
despite completing the treatment. There was a significant effect of this 2nd 
treatment (F1,7= 7.703, p=.027) on the primary outcome measure when the 
end of second treatment scores were compared to pre-treatment. There was 
no change in YBOCS severity ratings for the 3 participants who completed 
AM following CBT although the individuals attended readily and qualitatively 
commented that they found the treatment helpful in general stress 
management.  
 
Secondary Outcome Measures 
Although clinician ratings of Clinical Global Impression (CGI) changed 
significantly between pre-and post treatment (F=29.1, df=1,34, p<.001), this 
did not vary by treatment group (F=2.28, df=1,34, p=.140). Figure 3 depicts 
the percentage of participants in each group rated as ‘much or very much 
improved’ and ‘minimally improved, unchanged or worse’ on the CGI 
improvement scale. On the basis of this dichotomous rating, the treatment 
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groups differ significantly in terms of the proportion of participants in each 
group rated as  ‘much or very much improved’ (CBT group n=11; AM group 
n=5;  (2=3.886 (df=1), Fisher’s exact test p=0.050). 
 
Figure 3 about here 
 
Regarding self-report measures, neither of the groups showed significant 
differences between pre-, post- and 1 month follow-up mean scores on any 
of the self-ratings (See table 3). Informant ratings differed significantly 
between pre- and post-treatment only for the AM group.  
Moderating Factors 
Symptom Severity 
The 5 participants classified as treatment responders in the AM group had 
significantly lower YBOCS severity ratings pre-treatment (mean=21.20, 
sd=3.2) when compared to the non-responders in the AM group 
(mean=26.8, sd=4.8; t=2.37 (df=17); p=.029, 95% C.I. 0.6-10.6). This was 
not the case in the CBT group where responders and non-responders were 
equivalent with respect to symptom severity before starting treatment (CBT 
responder mean =24.8, sd=3.2; CBT non-responder mean =24.1, sd=4.4; t=-
.41 (df=16), p=.687). Similarly, treatment responders in the AM group had a 
significantly lower CGI rating pre-treatment than non-responders (AM 
responders mean=3.2, sd=.5; AM non-responders mean=4.5, sd=.6; t=3.56, 
df=15, p=.003, 95% C.I. 0.5-2.0). The AM responders did not differ in terms 
of number of OC symptoms from non-responders.  
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Age 
Age was not significantly associated with treatment outcome. The main 
outcome analysis was also repeated excluding those participants who 
entered the Youth protocol (Age 14-16) and this did not affect the pattern of 
results. 
 
Other variables 
Other variables purported to be of interest as potential moderators of 
treatment including Verbal IQ, ADOS scores and performance on executive 
function measures were investigated in terms of their association with 
treatment response i.e. the percentage change in total YBOCS severity 
scores.  None of these factors showed any association.   
 
However, the group categorized as treatment responders (i.e. >25% 
reduction in YBOCS ratings) differed significantly from non-responders on 
the Family Accommodation Scale (FAS) at baseline (Mean treatment 
responder FAS=18.22, s.d.=15.91; Mean treatment non-responder FAS 
score=29.53, s.d.=12.30; t=2.015, df=24, p=.055, 95% C.I. of the difference -
.275-22.89). The treatment responder and non-responder groups did not 
differ on the FAS at the end of treatment. There was a wide range of scores 
on the FAS in the treatment response group at baseline and this reduced by 
the end of treatment suggesting that family factors may have changed over 
the course of treatment.  
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In terms of insight as ascertained by the Y-BOCS, 33 (71.7%) of all 
participants could identify a specific feared consequence if they did not 
respond to the obsessive thoughts or compulsive urges. Certainty about the 
feared consequences differed post-treatment according to treatment 
response at the trend level (responder mean rating=1.00 (sd=1.15), non-
responder mean rating=1.95 (sd=1.07); t=2.00 (df=26), p=.056), indicating 
that non-responders tended to have worse insight scores.  
 
 
Discussion 
 
This is the first clinical trial to provide evidence for the effectiveness of CBT 
for co-morbid OCD in young people and adults with ASD. The effect of CBT 
treatment in the present study was comparable to clinical trials of OCD in 
people without ASD where aggregated effect sizes of 1.12 and 1.45 have 
been reported from meta-analyses of CBT trials in adult42  and pediatric43 
OCD studies respectively  Importantly, the treatment gains were sustained 
over a 12-month follow-up period.  
 
Unexpectedly, Anxiety Management, a plausible control treatment, was also 
effective in bringing about a reduction in OCD symptoms in people with ASD, 
particularly those with milder symptoms. It was not possible to separate the 
two treatment groups at the end of treatment in terms of symptom severity, 
although there were twice as many responders in the CBT than in the AM 
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group. Comparison between the effect sizes of the two treatments afforded 
some small advantage for ERP-based CBT over AM.  
 
This advantage for CBT was greater for ratings of obsessions. In an earlier 
uncontrolled pilot study18 where CBT was compared with treatment as usual, 
we noted an overall advantage for CBT, with a significant change in 
obsessions severity ratings but not compulsions. It is possible that 
measurement issues and in particular difficulties in disentangling ASD 
preferred routines and stereotyped behaviours from anxiety based 
compulsions has a role to play here. Alternatively, unwanted intrusive 
thoughts/images/impulses may be associated with greater distress and thus 
motivation for treatment than compulsive rituals where a preference for 
routine and sameness in ASD may infer greater tolerance of these 
symptoms. Further, outcome for adults with ASD is known to be poor with 
low levels of employment and independent living. In the absence of full-
occupation, compulsive rituals may not present with a high level of daily 
interference.   
 
Significantly more patients in the AM group requested crossover to the CBT 
group than did CBT patients to the AM group after the 1-month follow-up 
than, indicating that the AM treatment although receiving similar satisfaction 
ratings, was not perceived as being as potentially useful as the ERP based 
treatment. The 8 patients who crossed over from AM to CBT and provided 
data at the 1-month follow-up point achieved statistically significant 
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reductions in OCD severity, whereas those who crossed over from CBT to 
AM (n=3) did not improve. 
 
Setting aside the not inconsequential issues of sample size and statistical 
power (discussed below), it is worth considering why AM might have 
performed relatively well in people with ASD and co-morbid OCD, 
particularly those with mild symptoms.  
 
First, this is not an unprecedented finding. For example, Whittal et al. 
(2010)44 in a study investigating Cognitive Therapy for obsessions found that 
Stress Management (a credible control treatment) was also helpful in 
reducing obsessions with equivalent pre-post effect sizes for both treatments 
on the primary outcome measure. Unexpectedly, changes in OCD related 
cognitions and threat appraisals occurred in the control group. In an internet-
based trial of self-help for panic and phobias26, a similar anxiety 
management control group did as well as the exposure therapy group on 
some outcome measures. In an ASD specific study of group treatment for 
anxiety in children, a social recreational programme was found to have a 
similar effect on anxiety symptoms as CBT45. Thus, under certain 
circumstances, non-specific interventions can lead to clinically significant 
improvements in disorder-specific measures. In the current trial, it is 
important to note that patients who responded to the control treatment had 
significantly less severe OCD.  
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Second, it is important to consider that OCD is not the only commonly 
occurring anxiety disorder in ASD. There is evidence that processing and 
identification of emotions may be impaired in this group46 and the AM 
intervention in the present study (with its focus on education about anxiety 
and teaching of relaxation techniques), may have made anxiety a more 
predictable and manageable emotion for some individuals. Risk factors for 
anxiety disorders such as increased intolerance of uncertainty and anxiety 
sensitivity may be elevated in people with ASD who have a preference for 
routine and sameness and this may represent a pathway to OCD. Increasing 
an individual’s capacity to manage the emotional consequences brought 
about by uncertainty and anxiety may thus bring about a reduction in OCD 
symptoms.  
 
Further, the non-specifics of therapy may be more potent in this group who 
can be socially isolated and lack support. The majority of clinical trials in 
people with ASD have to date employed a wait list or treatment as usual 
comparison condition. However, an RCT evaluating CBT for anxiety versus a 
Social Recreational Program in young people with ASD had similar 
difficulties to the present study in significantly separating the treatments in 
terms of their effects on anxiety45. 
 
There were no therapist effects in terms of numbers of treatment 
responders. Prior to their work on the present study, the majority of the 
therapists had gained some experience of working with people with ASD as 
part of generic anxiety/OCD clinic work. Only one of the therapists had 
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previously worked in an ASD-specific service. Thus the results should be 
generalizable to clinicians and psychological therapists trained in treating 
OCD. 
 
Self-report of OCD and other anxiety symptoms were correlated with 
clinician and informant ratings at pre-treatment but not at follow-up 
suggesting they were not sensitive to change.  Nonetheless, it is of benefit to 
know that self-report measures can be used as an assessment tool to 
accurately assess the content of anxiety related problems in young people 
and adults with ASD and this is consistent with findings from other studies47. 
It is also important to note that many of the participants in the study had 
good insight into their OCD and that OC related beliefs were prevalent. 
 
There was some indication that family factors (family accommodation) were 
associated with treatment outcome in the present study and this is consistent 
with findings of other anxiety intervention studies in ASD5 and outcome in 
general pediatric OCD treatment studies40 . Group and individual 
psychological interventions for anxiety disorders in this group should then 
seek the engagement of relevant care-giving/supportive individuals in 
treatment.   
 
 
Limitations 
While the study was well powered to detect within-group changes in 
symptom severity, it may have lacked statistical power to detect a difference 
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between the two treatment groups. The power calculation was based on an 
earlier pilot study where treatment was compared to no-treatment18. As 
discussed above, the AM intervention clearly had some modest effect, 
particularly in individuals with mild OCD symptoms. This indicates that larger 
sample sizes will be needed to detect a statistically significant difference 
between the groups. The results of the current trial will be useful to help 
more accurate power calculations for future trials. However, the main 
message of the current study is that standard CBT for OCD can be 
successfully adapted for ASD participants who are traditionally perceived as 
difficult to treat.  
 
The disproportionally high number of participants who endorsed hoarding 
symptoms in the CBT (60%) vs. the AM (40%) groups may also have 
contributed to the lack of clearly significant differences between the groups 
because hoarding symptoms are usually considered difficult to treat with 
conventional CBT for OCD48. Given the current proposals to separate 
hoarding from OCD in DSM-549, future treatment studies would probably 
benefit from excluding any severe hoarding individuals from their samples. 
 
The wide ranges of age and symptom severity may have had an impact on 
the findings. Rounsaville et al. (2001)48 recommend reducing therapist and 
participant heterogeneity and choosing narrow parameters with which to 
define the treatment setting, participants and therapists in order to optimize 
the power available in a small pilot trial. However, we felt that as a proof of 
concept trial, it would be important to recruit a wide range of individuals.  
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The lack of follow-up information on the AM group is a weakness imposed by 
our design, as it was unethical to withhold the evidence based treatment 
(CBT) for longer than the 1-month follow-up and these patients had to be 
offered the option of a cross-over.  A further limitation was the absence of 
detailed information about homework compliance and its association with 
treatment response.  
 
Not everyone did well as a result of treatment. A proportion of participants in 
both groups (15% AM and 10% CBT) were rated as minimally or much 
worse at 1 month follow-up on the Clinical Global Impressions Scale, one of 
the secondary outcome measures. In addition to the lack of longer term 
follow-up previously mentioned in the AM group, just over 50% of the 
treatment completers in the CBT group remained in follow-up for 12 months. 
It is possible that those lost to follow-up may also have deteriorated during 
that period and thus the positive effects of the intervention may have been 
limited to just those who stayed in the study.  
 
In summary, psychological treatments for OCD can be successfully adapted 
for comorbid ASD and OCD. Further testing of these promising interventions 
with larger, more homogeneous samples is now required. 
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Figure 1: Consort Flow Diagram 
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Table 1:  Correlations of Clinician, Informant and Self-report severity ratings of OC symptoms 
Rating Informant 
Obsessions 
severity  
Informant 
Compulsions 
severity 
Informant 
total 
severity  
Clinician 
total 
severity  
Self-
report 
Washing  
Self-
report 
Hoarding 
Self-
report 
Ordering 
Self-
report 
Obsessing 
Self-report 
Neutralising 
Clinician 
Obsessions 
severity  
.481 
p=.020 
n=23 
        
Clinician 
Compulsions 
Severity 
 .276 
p=.155 
n=28 
       
Clinician total 
severity  
  .576 
p=.001 
n=28 
      
Self-report 
total severity 
  .482 
p=.015 
n=25 
.265 
p=.108 
n=38 
     
Clinician 
Contamination 
severity 
    .468 
p=.003 
n=39 
    
Clinician 
Hoarding 
severity 
     .394 
p=.014 
n=38 
   
Clinician 
Symmetry 
severity 
      .374 
p=.019 
n=39 
  
Clinician 
Aggression 
Obs severity  
       .419 
p=.01 
n=37 
.462 
p=.003 
n=38 
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Table 2:  Age, ADOS, Verbal IQ and Symptom Measures at pre-treatment 
ADOS Comm and RSI total: Autism Diagnostic Observation Schedule 
Communication and Reciprocal Social Interaction domains scores total 
WAIS: Wechsler Adult Intelligence Scales 
WISC: Wechsler Intelligence Scales for Children
 Anxiety 
Management 
Group 
Mean (SD) 
 
CBT Group 
Mean (SD) 
t (df) p 
Age in years 25.2 (13.5)  
Min=14 
max=65 
28.6 (11.3) 
Min=14 
max=49 
-.93 (44) 1.00 
ADOS Comm and RSI total 9.9 (4.7) 10.7 (4.2) -.49 (33) .621 
WAIS/WISC Verbal IQ 97.3 (15.2) 102.5 (16.7) -.91 (30) .367 
Clinician administered 
YBOCS Obsessions severity 12.4(3.1) 11.6 (2.7)  .90(39) .370 
YBOCS Compulsions severity 12.9(2.8) 13.2(1.5) -.47(39) .638 
YBOCS total severity 25.1(5.2) 24.8(3.7)  .20(39) .839 
DYBOCS Global severity 20.4(5.1) 20.6(3.7) -.15(41) .880 
CGI   4.2(0.8)   4.1(0.7)  .35(37) .725 
Self-Report 
OCI-R: 
        Checking sub-scale 
        Hoarding sub-scale 
        Neutralising sub-scale 
        Obsessing sub-scale 
        Ordering sub-scale 
        Washing sub-scale 
         OCI-R Total 
 
5.8(3.6) 
5.1(3.6) 
2.8(3.4) 
6.6(3.6) 
6.6(3.2) 
 4.3 (4.1) 
30.9(13.7) 
 
6.4(3.7) 
5.2(3.6) 
3.3(3.0) 
6.4(4.0) 
5.3(4.4) 
 3.8(3.8) 
30.5(15.9) 
 
-.37(33) 
-.19(33) 
-.58(33) 
  .26(32) 
  .16(34) 
  .16(34) 
  .09(34) 
 
.708 
.849 
.566 
.790 
.256 
.869 
.929 
Beck Depression Inventory 16.9(12.0) 17.3(13.5) -.11 (38) .912 
Beck Anxiety Inventory  15.4 (10.9) 
N=15 
16.2(11.6) 
N=17 
-.19 (37) .725 
Spence Children’s Anxiety 
Scale Total Score 
27.8(4.7) 
N=5 
28.3(20.3) 
N=3 
-.05 (6) .955 
Liebowitz Social Anxiety Scale 
Total Score                 
76.8(26.1) 
 
67.5(33.5) 
 
 .82(26) .418 
Work and Social Adjustment 
Scale 
18.5(9.5) 18.8(10.9) -.069 (30) .946 
Parental/Carer Report     
CHOCI Symptom Total 14.7(8.1) 14.4(6.0)  .11(25) .908 
CHOCI Impairment Total 28.9(12.5) 27.9(11.6)  .21(25) .832 
Family Accommodation Scale 
(n=27) 
24.1(13.5) 27.3(15.1) -.58(25) .562 
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Table 3;  Pre and post treatment and 1 Month Follow-up  clinician, self and informant ratings by group 
 Pre-
Treatment 
Mean (SD) 
Post 
treatment  
Mean (SD) 
1 Month 
FUP 
Mean (SD) 
Pre-Post 
difference 
Mean 95% 
C.I. 
Pre-1MFUP 
difference 
Mean 95% 
C.I. 
Pre-Post % 
imp. 
Mean (SD) 
Pre-1MFUP 
% imp. 
Mean (SD) 
Pre-
Post 
effect 
size 
Pre-
1MFU 
Effect 
size 
CBT: Clinician ratings 
YBOCS: 
   Total severity 
   Obsessions severity 
   Compulsions severity 
CGI 
Dimensional YBOCS: 
     Contamination  
     Hoarding        
     Symmetry      
     Aggression/Harm  
     Sexual/Religious    
     Miscellaneous 
     Global total 
 
 
24.8(3.7) 
11.7(2.8) 
13.1(1.5) 
 4.2(0.8) 
 
7.3(4.1) 
3.5(3.9) 
5.3(4.5) 
3.8(4.3) 
2.0(3.1) 
3.2(4.1) 
20.7(3.8) 
 
 
17.8(8.4) 
8.7(4.1) 
9.0(4.6) 
3.3(1.1) 
 
3.9(3.8) 
1.7(2.8) 
4.2(4.6) 
2.6(4.0) 
1.2(2.3) 
1.4(3.0) 
15.5(7.1) 
 
 
18.7(8.2) 
8.5(3.6) 
9.7(4.5) 
3.5(1.3) 
 
4.5(3.8) 
1.7(2.8) 
4.6(4.4) 
2.2(3.5) 
1.3(2.5) 
1.6(3.5) 
15.8(7.0) 
 
 
7.0** 3.2-10.7 
2.9** 1.1-4.7 
4.0** 1.7-6.3 
0.9***0.4-1.4 
 
3.4** 1.4-5.3 
1.7*  0.2-3.3 
1.1   -.2-2.5 
1.2   -.1-2.5 
0.8  -.2-1.8 
1.8*   0.4-3.1 
5.2*** 2.5-7.8 
 
 
5.8***. 2-9.7 
3.1** 1.4-4.7 
3.2** 0.9-5.5 
0.8** 0.2-1.4 
 
2.6**  0.8-4.5 
2.1*  0.3-3.9 
1.2   -.3-2.8 
1.8*  .2-3.4 
0.8   -.3-1.9 
1.7*  .1-3.2 
5.0** 2.1-7.9 
 
 
27.8(33.2) 
24.0(34.7) 
29.7(36.5) 
21.4(21.8) 
 
41.4(48.6) 
48.8(55.7) 
35.5(47.1) 
29.9(61.7) 
37.3(51.4) 
60.6(45.4) 
26.7(30.1) 
 
 
23.5(32.1) 
25.2(30.9) 
23.9(35.7) 
19.6(25.3) 
 
34.2(41.3) 
53.4(49.5) 
34.9(48.0) 
65.7(39.3) 
34.7(52.8) 
58.5(52.6) 
25.4(30.9) 
 
 
1.078 
 .854 
1.198 
 .935 
 
.860 
.530 
.241 
.288 
.293 
.501 
.913 
 
 
 .958 
 .922 
1.013 
 .648 
 
.708 
.530 
.157 
.408 
.248 
.419 
.870 
CBT: Self-Ratings: 
    OCI-R total  
    BDI 
    BAI 
    Liebowitz total 
    Spence total 
    Work and Social 
    Adjustment Scale 
 
31.5(12.7) 
16.2(13.8) 
16.4(10.6) 
74.7(27.1) 
28.3(20.3) 
19.0(10.4) 
 
 
26.8(15.3) 
15.7(16.5) 
14.0(11.6) 
67.8(34.9) 
 
22.4(11.7) 
 
29.3(12.9) 
17.5(15.1) 
13.6(10.1) 
66.2(35.7) 
49.0(n=1) 
14.1(9.1) 
 
4.7   -1.3-10.7 
-.5  -3.9-4.9 
2.3   -0.8-5.5 
6.9 -9.8-23.7 
 
3.4   -7.8-1.0 
 
1.3   -6.9-9.7 
2.0   -2.9-6.9 
1.5  -3.8-6.9 
-2.2-17.6-13 
 
4.6  -3.9-13.1 
 
20.2(45.8) 
17.9(58.3) 
14.1(52.9) 
 7.0(34.7) 
20.0 
-24.4(43.5) 
 
-32.1(97.4) 
16.4(39.1) 
26.5(36.0) 
-20.3(46.2.1) 
-28.9 
8.4(53.5) 
 
.334 
.032 
.215 
.220 
 
-.307 
 
.171 
-.089 
.270 
.268 
-1.40 
.501 
CBT:Informant: 
    CHOCI severity  
     Family Acc. 
 
30.3(11.1) 
26.9(15.2) 
 
25.8(10.5) 
27.9(15.0) 
 
28.8(7.0) 
21.1(9.3) 
 
4.5  2.1-11.1 
-1  -11-8.9 
 
2.7-7.5-13.0 
6.3  -5.8-18.4 
 
 4.9(41.1) 
-33.1(90.1) 
 
-3.2(41.2) 
1.4(71.3) 
 
.416 
-.066 
 
.161 
.460 
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Pre-
Treatment 
Mean (SD) 
Post 
treatment  
Mean (SD) 
1 Month 
FUP 
Mean (SD) 
Pre-Post 
difference 
Mean 95% 
C.I. 
Pre-1MFUP 
difference 
Mean 95% 
C.I. 
Pre-Post % 
imp. 
Mean (SD) 
Pre-1MFUP 
% imp. 
Mean (SD) 
Pre-
Post 
effect 
size 
Pre-
1MFU 
Effect 
size 
AM: clinician ratings 
YBOCS: 
   Total severity  
    Obsessions severity 
    Compulsions  
CGI 
Dimensional YBOCS: 
     Contamination   
     Hoarding 
     Symmetry  
     Aggression/Harm  
     Sexual/Religious    
     Miscellaneous 
     Global total 
 
 
25.1(5.1) 
12.4(3.0) 
12.9(2.8) 
 4.2(0.8) 
 
5.8(4.3) 
2.9(3.8) 
5.4(4.3) 
6.5(4.4) 
1.6(3.4) 
3.3(4.2) 
20.3(4.7) 
 
 
20.8(7.8) 
10.5(3.8) 
10.3(4.7) 
3.7(1.1) 
 
4.8(4.8) 
2.5(3.6) 
4.6(3.9) 
5.3(4.6) 
2.2(4.2) 
1.6(4.7) 
17.1(7.5) 
 
 
20.7(5.4) 
11.9(2.3) 
10.8(3.0) 
3.7(1.2) 
 
4.9(4.4) 
2.0(3.4) 
3.7(3.7) 
4.5(4.1) 
2.2(4.2) 
1.1(2.2) 
17(5.9) 
 
 
4.7***2.5-6.8 
2.0** 0.9-3.0 
2.7** 1.1-4.3 
0.5** 0.2-0.8 
 
1.0   -.5-2.5 
0.3   -1.4-2.1 
0.8   -.6-2.2 
1.2   -.1-2.6 
-.6   -2.4-1.2 
1.6* 0 .2-3.0 
3.2** 1.1-5.2 
 
 
3.8***2.1-5.6 
2.2***1.2-3.3 
1.9*  0.9-3.1 
0.6**  0.1-0.9 
 
0.8   -.6-2.2 
0.8   -1.4-3.1 
2.0*  .2-3.7 
2.1*  .27-3.9 
-1.0  -2.8-.8 
1.9*   -0.2-3.9 
2.9** 1.3-4.5 
 
 
20.3(23.4) 
17.6(21.9) 
22.5(30.6) 
13.9(18.4) 
 
22.3(69.6) 
54.9(36.0) 
21.8(40.8) 
29.4(37.7) 
52.5(55.0) 
58.9(46.8) 
18.5(27.1) 
 
 
16.2(14.3) 
19.7(17.9) 
13.1(20.8) 
14.9(19.6) 
 
27.6(45.0) 
68.7(39.2) 
43.1(43.2) 
36.8(41.7) 
19.5(14.7) 
51.5(50.8) 
15.7(14.9) 
 
 
.652 
.554 
.672 
.519 
 
.219 
.108 
.194 
.266 
-.157 
.381 
.511 
 
 
.837 
.187 
.723 
.490 
 
.206 
.249 
.423 
.470 
-.157 
.656 
.524 
AM: self-ratings: 
    OCI-R total  
    BDI 
    BAI 
    Liebowitz total 
    Spence total 
    Work and Social 
    Adjustment Scale 
 
30.3(11.9) 
17.1(12.4) 
16.6(12.2) 
72.4(29.1) 
27.5(3.5) 
17.9(9.5) 
 
30.9(13.4) 
17.5(12.0) 
17.2(12.7) 
78.8(43.7) 
36.5(13.4) 
17.2(7.5) 
 
31.1(14.4) 
18.8(12.3) 
15.4(13.1) 
76.4(37.1) 
36.0(14.1) 
15.7(6.3) 
 
-.5   -5.2-4.2 
-.4   -5.2-4.3 
-.5   -5.6-4.5 
-5.7  -29-17.6 
-7   -95-81.9 
0.6   -4.9-6.2 
 
-.06  -4.6-4.5 
-1.3   -7.2-4.6 
-.6   -4.0-5.4 
-3  -15.3-19.1 
-8.5-103-86.7 
.92   -4.6-6.5 
 
-4.3(28.7) 
-10.2(60.3) 
-23.1(97.5) 
-11.0(56.9) 
-23.3(32.9) 
-28.6(85.9) 
 
-.68(23.5) 
-16.7(85.9) 
 4.3(60.2) 
-0.5(30.4) 
-28.6(34.8) 
-50.6(167.9) 
 
-.047 
-.032 
-.048 
-.172 
-.919 
.081 
 
-.060 
-.137 
.094 
-.119 
-.827 
.272 
AM:Informant: 
    CHOCI severity  
     Family Acc. 
 
27.8(12.7) 
20.8(13.1) 
 
21.0(13.5) 
22.3(17.2) 
 
20.3(15.4) 
17.8(17.1) 
 
6.8*  -.1-13.7 
-1.5  -9.1-6.1 
 
4.1  -4.4-26.6 
.2  -9.7-12.2 
 
21.6(56.7) 
-7.0(50) 
 
19.9(48.1) 
5.0 (55.7) 
 
.518 
-.098 
 
.531 
.196 
AM=anxiety management, 1MFUP=one month follow-up ratings 
Significance of change on 2-tailed related test *<.05, **<.01, ***<.001 
 42
 
 
 
 43
Figure 2:  YBOCS total severity (pre and end treatment, 1M FUP) by 
treatment group and 3 (n=10), 6 (n=12) and 12M (n=11) FUP for CBT group 
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Figure 3: Percentage of participants rated as ‘minimally improved, unchanged or 
worse’ and ‘much or very much improved’ on the Clinical Global Improvement 
Scale by treatment group 
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Description of the treatments 
CBT treatment 
The duration of each session ranged from 41 to 74 minutes (mean session 
length=60 minutes, s.d=7.5). Homework was set at every session, which 
included reading materials from the session, completing OCD diaries and 
exposure tasks. The compliance rate for homework was 90%, although this 
included even partial completion of the homework tasks. On average 10 
(s.d=5.4) ERP tasks were set as homework throughout treatment and the 
compliance rate for these was 79%. The mean compliance rate for other 
homework such as reading materials and keeping records was 89%.  In 
terms of session content and how the treatment was generally structured, a 
mean of 2.7 sessions (s.d=1.6, range 1-6) comprised anxiety education; 
OCD education was included in 3 to 13 sessions (mean=5.8, s.d.=2.9);  
Exposure and Response Prevention (ERP) was covered in up to 16 sessions 
(mean=8.6, s.d.=5.3) and a mean of 2.7 sessions (s.d.=3.2) included 
cognitive intervention techniques.  Relapse prevention took between 0 to 2 
(mean=1, s.d.=0.7) sessions. 
 
In terms of the frequency of using ASD specific modifications,  work with 1 
participant incorporated the use of their special interest to help convey 
concepts, therapists were noted on the record forms as needing to be ‘more 
directive’ in sessions for 13 (68%) of participants,  6 (32%) participants 
needed ‘rules’ to engage with the structure of the sessions (e.g. how much 
time to spend talking on non-OCD topics etc),  9 (47%) of participants’ 
sessions record forms had reference to concrete examples being needed 
and use of visual material to convey concepts was incorporated in 11 (58%) 
of participants’ sessions. Nine (47%) participants in the CBT group had 
direct involvement of parents/carers in sessions.   
 
Anxiety management treatment 
The duration of the sessions ranged from 28 to 71 minutes (mean=57 
minutes, s.d.=8.3). Homework was set at every session, which included 
reading materials, practicing techniques learnt in the sessions and keeping 
records. The compliance rate for homework was 95%, which included even 
partial completion of the homework tasks.  
 
With regards to content of the treatment, between 1 to 8 sessions were 
focused on learning and practicing breathing exercises (mean=3.9, s.d.=1.8) 
and between 1 to 13 sessions included relaxation practice (mean=5.5, s.d. 
=3.1). Sessions on mood ranged from 0 to 3 (mean=1.4, s.d.=0.82), 0 to 10 
sessions were on healthy habits (mean= 3.9, s.d.= 2.7) and 0 to 4 sessions 
were spent on problem solving (mean =1.9, s.d.= 1.2). 
 
In terms of modifying the AM treatment to make it suitable for people with 
ASD, there were no records suggesting any participants had their special 
interests incorporated into the session. Therapists were noted as being 
 47
‘more directive’ in sessions for 5 (25%) of participants, 1 (5%) participant 
needed rules for the sessions, 6 (30%) needed reference to concrete 
examples, 9 (45%) needed visual aids and 6 (30%) of participants’ 
parents/carers were directly involved in sessions.   
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